Qifa Liu
Nanfang Hospital, Southern Medical University
Emerging Leaders
not ranked
Current Leaders
#9029 pts
All-Time Leaders
#4268 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2012. 4 trials as lead/chair. How it works →
Trials led — by scientific impact
Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis
Phase 4CompletedNanfang Hospital, Southern Medical University
5
impact
The Efficacy and Safety of Luspatercept in Preventing Poor Erythroid Engraftment After Allo-HSCT for Hematological Malignancies With Moderate to Severe Myelofibrosis: A Prospective, Multicenter, Randomized Controlled Study
Phase 3Not Yet RecruitingNanfang Hospital, Southern Medical University
5
impact
Luspatercept Versus Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies
Phase 2Not Yet RecruitingNanfang Hospital, Southern Medical University
4
impact
Mesenchymal Stem Cells Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation
Phase 3UnknownNanfang Hospital, Southern Medical University
4
impact
Sorafenib for Prophylaxis of Leukemia Relapse in Allogeneic Hematopoietic Stem Cell Transplant Recipients With FLT3-ITD Positive Acute Myeloid Leukemia
Phase 3CompletedNanfang Hospital, Southern Medical University
4
impact
Venetoclax+Decitabine+Busulfan+Fludarabine (VEN+DAC+Bu2Flu4) vs Busulfan+Fludarabine Conditioning Regimen (Bu2Flu5 ) for Older Patients With Myeloid Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
Phase 3Not Yet RecruitingNanfang Hospital, Southern Medical University
3
impact
Minimal Residual Disease-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allogenetic Hematopoietic Stem Cell Transplantation
Phase 3CompletedNanfang Hospital, Southern Medical University
3
impact
Allogeneic Stem Cell Transplantation With Alternative Donor in Treatment of Hematologic Malignancy
N/ACompletedNanfang Hospital, Southern Medical University
3
impact
Tyrosine Kinase Inhibitor Therapy Based on Molecular Monitoring of BCR/ABL Transcript Levels in Allogeneic Hematopoietic Stem Cell Transplant Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Phase 2UnknownNanfang Hospital, Southern Medical University
3
impact
Efficacy and Safety of HVA Regimens as Salvage Treatment in Relapsed/Refractory (rr) Acute Myeloid Leukemia (AML)
Phase 2CompletedNanfang Hospital, Southern Medical University
3
impact
A Comparison of PTCy-ATG and ATG Strategy in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis
Phase 4UnknownNanfang Hospital, Southern Medical University
3
impact
Mesenchymal Stem Cells From Third-party Donors for Treatment of Refractory Acute Graft-versus-host Disease
Phase 2UnknownNanfang Hospital, Southern Medical University
2
impact
Prospective Evaluation of Sorafenib Combined With Standard Therapy in Newly Diagnosed Adult Core-binding Factor Acute Myeloid Leukemia: an Open-label , Randomised Controlled, Multicenter Phase II Trial
Phase 2UnknownNanfang Hospital, Southern Medical University
2
impact
Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for Patients With FLT3-ITD Positive Acute Myeloid Leukemia
N/ACompletedNanfang Hospital, Southern Medical University
2
impact
Mesenchymal Stem Cell for Treatment of Interstitial Lung Disease After Allogenetic Hematopoietic Stem Cell Transplantation
Phase 2UnknownNanfang Hospital, Southern Medical University
2
impact
Busulfan Plus Cyclophosphamide vs Total Body Irradiation Plus Cyclophosphamide Conditioning Regimen for Standard-risk Acute Lymphocytic Leukemia Undergoing HLA-matched Allogeneic Hematopoietic Stem Cell Transplantation
Phase 3CompletedNanfang Hospital, Southern Medical University
2
impact
Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis
N/AUnknownNanfang Hospital, Southern Medical University
2
impact
Mesenchymal Stem Cells for Treatment of CMV Infection After Hematopoietic Stem Cell Transplant
Phase 2UnknownNanfang Hospital, Southern Medical University
2
impact
Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure Following Autologous Hematopoietic Stem Cell Transplantation
Phase 2UnknownNanfang Hospital, Southern Medical University
2
impact
Mesenchymal Stem Cells From Third-party Donors for Treatment of Refractory Chronic Graft-versus-host Disease
Phase 2UnknownNanfang Hospital, Southern Medical University
2
impact
Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia in Patients With Acute Leukemia Receiving Chemotherapy
Phase 3UnknownNanfang Hospital, Southern Medical University
2
impact
Idarubicin+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Intermediate-risk Acute Myeloid Leukemia Undergoing Autologous Hematopoietic Stem Cell Transplantation
Phase 3CompletedNanfang Hospital, Southern Medical University
1
impact
Risk-stratified Therapy Based on Molecular and Cytogenetic Aberration and Treatment Response in Acute Myeloid Leukemia
N/AUnknownNanfang Hospital, Southern Medical University
1
impact
Hypomethylating Agents + Donor Lymphocyte Infusion vs Donor Lymphocyte Infusion Preemptive Therapy Based on Minimal Residual Disease for Acute Leukemia Undergoing Allogenetic Hematopoietic Stem Cell Transplantation
Phase 3UnknownNanfang Hospital, Southern Medical University
1
impact
G-CSF Mobilized Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant
Phase 2UnknownNanfang Hospital, Southern Medical University
1
impact
Mesenchymal Stem Cells With or Without G-CSF Mobilized Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplant
Phase 3UnknownNanfang Hospital, Southern Medical University
1
impact
Mesenchymal Stem Cells From Third-party Donors for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation
Phase 2UnknownNanfang Hospital, Southern Medical University
1
impact
Hematopoietic Stem Cell Microtransplantation for Acute Myeloid Leukemia
N/AUnknownNanfang Hospital, Southern Medical University
1
impact
A Comparative Study of Haploidentical Transplantation Supported by Third-party Cord Blood and Haploidentical Transplantation in Hematological Malignancies
Phase 3CompletedNanfang Hospital, Southern Medical University
0
impact
Granulocyte Colony-stimulating Factor+Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Patients With RAEB-1, RAEB-2 and AML Secondary to MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Phase 3CompletedNanfang Hospital, Southern Medical University
0
impact
Efficacy and Safety of Targeted Drugs Combined With Chemotherapy in the Treatment of Patients With Newly Diagnosed Acute T-lymphocytic Leukemia
Phase 3RecruitingNanfang Hospital, Southern Medical University
0
impact
G-CSF+DAC+BUCY vs. G-CSF+DAC+BF Conditioning Regimen for Patients With High-risk MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Phase 3UnknownNanfang Hospital, Southern Medical University
0
impact
G-CSF+DAC+BUCY vs. G-CSF+DAC+BF Conditioning Regimen for Patients With RAEB-1, RAEB-2 and AML Secondary to MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Phase 3UnknownNanfang Hospital, Southern Medical University
0
impact
Investigator-initiated Trial to Explore the Efficacy and Safety of Fecal Microbiota Transplant (FMT) Capsule in the Treatment of Steroid-refractory Gastrointestinal Acute Graft Versus Host Disease Patients
N/AUnknownNanfang Hospital, Southern Medical University
0
impact
Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allogeneic Hematopoietic Stem Cell Transplant Recipients With FLT3 Negative Acute Leukemia
Phase 3UnknownNanfang Hospital, Southern Medical University
0
impact
Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Myeloid Tumors Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Phase 3UnknownNanfang Hospital, Southern Medical University
0
impact
ATG Used in Allogeneic Hematopoietic Stem Cell Transplantation From HLA-matched Sibling Donor as GVHD Prophylaxis
Phase 4UnknownNanfang Hospital, Southern Medical University
0
impact
Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Phase 3UnknownNanfang Hospital, Southern Medical University
0
impact
Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Mixed-lineage-leukemia (MLL)-Rearranged Acute Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Phase 3UnknownNanfang Hospital, Southern Medical University
0
impact
Effect of Prophylactic Tyrosine Kinase Inhibitor Therapy Post-transplants on Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Undergoing Allo-HSCT With Minimal Residual Disease Positive Pre-transplants
Phase 3UnknownNanfang Hospital, Southern Medical University
0
impact
The Effect of Granulocyte-colony Stimulating Factor (G-CSF) on Minimal Residual Disease (MRD) After Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
Phase 3UnknownNanfang Hospital, Southern Medical University
0
impact
Busulfan+ Cyclophosphamide+ Etoposide Conditioning Regimen for Primary Central Nervous System Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation
Phase 3UnknownNanfang Hospital, Southern Medical University
0
impact
Comparisiom of Standard (SD) Therapy and Non-standard (NSD) Therapy in Elderly Acute Myeloid Leukemia (AML)
N/AUnknownNanfang Hospital, Southern Medical University
0
impact
Busulfan+ Cyclophosphamide+ Etoposide vs Busulfan+ Cyclophosphamide Conditioning Regimen for Diffuse Large B-cell Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation
Phase 3UnknownNanfang Hospital, Southern Medical University
0
impact